There are numerous cell types with scarcely understood functions, whose interactions with the immune system are not well characterized. To facilitate their study, we generated a mouse bearing enhanced green fluorescent protein (EGFP)-specific CD8 + T cells. Transfer of the T cells into EGFP reporter animals can be used to kill EGFP-expressing cells, allowing selective depletion of desired cell types, or to interrogate T-cell interactions with specific populations. Using this system, we eliminate a rare EGFP-expressing cell type in the heart and demonstrate its role in cardiac function. We also show that naive T cells are recruited into the mouse brain by antigenexpressing microglia, providing evidence of an immune surveillance pathway in the central nervous system. The just EGFP death-inducing (Jedi) T cells enable visualization of a T-cell antigen. They also make it possible to utilize hundreds of existing EGFP-expressing mice, tumors, pathogens and other tools, to study T-cell interactions with many different cell types, to model disease states and to determine the functions of poorly characterized cell populations.
l e t t e r s
There are numerous cell types with scarcely understood functions, whose interactions with the immune system are not well characterized. To facilitate their study, we generated a mouse bearing enhanced green fluorescent protein (EGFP)-specific CD8 + T cells. Transfer of the T cells into EGFP reporter animals can be used to kill EGFP-expressing cells, allowing selective depletion of desired cell types, or to interrogate T-cell interactions with specific populations. Using this system, we eliminate a rare EGFP-expressing cell type in the heart and demonstrate its role in cardiac function. We also show that naive T cells are recruited into the mouse brain by antigenexpressing microglia, providing evidence of an immune surveillance pathway in the central nervous system. The just EGFP death-inducing (Jedi) T cells enable visualization of a T-cell antigen. They also make it possible to utilize hundreds of existing EGFP-expressing mice, tumors, pathogens and other tools, to study T-cell interactions with many different cell types, to model disease states and to determine the functions of poorly characterized cell populations.
The surface of all nucleated cells contain major histocompatibility (MHC) class I molecules that present peptides from endogenously expressed proteins 1 . CD8 + T cells scan the surface of cells, and engage only cells in which their T-cell receptor (TCR) has sufficient affinity for a specific peptide-MHC class I complex. The outcome of T-cell engagement is not only dependent on TCR affinity for the peptide-MHC complex, but also highly dependent on the nature of the cell presenting the antigen and the local mileu 2, 3 . Although we know how T cells interact with some cell populations, T-cell interactions with many cell types, especially rare cell populations, have never been specifically studied 3 .
The predominant means by which T-cell interactions with specific cell types have been studied is through the use of T cells engineered to express a TCR that recognizes a single peptide-MHC complex 4, 5 . These models have been invaluable in advancing our understanding of immunology 6, 7 . However, the study of T-cell interactions with their antigen-expressing targets has been limited by two factors in particular: technological difficulties in tracking and monitoring antigen-expressing cells and the lack of animals and reagents that express a model antigen in specific cell types.
Not only are there cell types whose interactions with the immune system are poorly studied, there are also cell populations whose functions have not been well characterized. This is also largely due to technological restrictions, in particular, the limitations of current methods to deplete specific cell populations. Depletion of a cell can be achieved using certain antibodies or by engineering mice to express the human diphtheria toxin receptor (DTR) under the control of a cell type-specific promoter and injecting diphtheria toxin (DT) 8, 9 . However, there are relatively few depleting antibodies or DTR mice available, and repeated administration of the antibody or DT, which can be toxic, is required to stably deplete cell types that are quickly renewed, such as lymphocytes.
To address these challenges, we reasoned that EGFP could be used as a model antigen. EGFP is readily detected by flow cytometry and fluorescence microscopy, and there are hundreds of EGFP-expressing mice available 10 , as well as EGFP-expressing cancer cell lines, viruses, bacteria and other tools. Here, we generated a mouse expressing an EGFP-specific TCR and show that this model enables wide-ranging studies of T-cell-tissue interactions and specific depletion of rare cell populations.
To generate mice expressing an EGFP-specific TCR, we used a somatic cell nuclear transfer (SCNT) approach 11 . The benefit of the SCNT approach is that the rearranged TCR is regulated at its endogenous locus and does not require the use of cultured T-cell clones. We crossed BALB/c and C57BL/6 mice, and immunized F 1 progeny mice (B6xBalbc) with a lentivirus encoding EGFP (LV.EGFP). After 2 weeks, we used a tetramer to isolate CD8 + T cells expressing TCRs specific for the immunodominant epitope of EGFP (EGFP [200] [201] [202] [203] [204] [205] [206] [207] [208] ) presented on H-2K d12 . We directly used the cells as a nuclear donor for SCNT (Fig. 1a) . We used B6xBalbc mice because SCNT is most efficient on a mixed background 11 , and because we wanted the EGFPspecific T cells to recognize EGFP presented on H-2K d . The H-2K d allele enables a diverse use because BALB/c, nonobese diabetic (NOD) and NOD/severe combined immunodeficient (SCID) mice all have 1 2 8 8 VOLUME 33 NUMBER 12 DECEMBER 2015 nature biotechnology l e t t e r s the H-2K d allele, and there are strains of C57BL mice with the H-2K d haplotype, most notably B6D2 and B10D2. Therefore, any mouse model on the C57BL/6 strain can be bred with DBA or B10D2 mice, and all first-generation progeny will express the H-2K d allele. In addition, knowledge of the immunodominant epitope presented on H-2K d allows detection of EGFP-specific CD8 + T cells with a tetramer. The F 1 mice were backcrossed for eight generations to B10D2 mice so that the mice (hereafter known as Jedi), expressed the H-2K d allele and were on the C57BL background. More than 50% of CD8 + T cells in all Jedi mice were specific for the GFP 200-208 -H-2K d pentamer, and their phenotype was naive (CD44 − CD62L + ) (Fig. 1b  and Supplementary Fig. 1 ). PCR analysis and Sanger sequencing revealed that the rearranged TCR was Vα1-J30 and Vβ4-D1-J1.6-C1 (Supplementary Fig. 2a) .
Monitoring antigen-expressing cells and their clearance by T cells is particularly relevant in viral immunology 13 . To determine if we could use our Jedi T cells to monitor removal of infected cells, we injected mice with LV.EGFP 14 , or with an LV encoding yellow fluorescent protein (LV.EYFP), which has >95% homology to EGFP, but differs by one amino acid in the immunodominant epitope (Supplementary Fig. 2b ). We then transferred CD8 + T cells from the Jedi or control mice.
In mice that received control T cells, ~2% of splenocytes were EGFP + , whereas in mice that received Jedi T cells, EGFP + cells were almost all eliminated, which indicated that Jedi T cells were capable of killing EGFP-expressing cells (Fig. 1c,d ). In contrast, splenocytes from mice infected with LV.EYFP were not killed (Fig. 1e) . To further assess the specificity of the Jedi T cells, we co-cultured them with dendritic cells expressing EGFP or EYFP and found that the T cells proliferated only in the presence of EGFP ( Fig. 1f and Supplementary Fig. 2c ). These results demonstrate the specificity and cytotoxic capacity of the Jedi T cells for EGFP-expressing cells.
Antigen-specific T cells have been used to model different autoimmune diseases 6 . A potential advantage of the Jedi T-cell approach over existing models is that it would enable qualitative and quantitative assessments at a cellular level, such as whether all target cells are killed. We set out to determine if we could use Jedi T cells to create a visualizable model of type I diabetes. We injected mice that express EGFP under the control of the mouse insulin promoter (MIP-EGFP) 15 with Jedi or control T cells and vaccinated them with EGFP to activate the transferred cells. Within 6 days of injecting Jedi T cells, we could not find any EGFP + beta-cells in the pancreas (Fig. 1g) . Through analysis of EGFP 200-208 -H-2K d pentamer + cells, we found that the EGFP-specific T cells had primarily localized to the pancreatic draining lymph node (Fig. 1h) and undergone proliferation (Fig. 1i) . Consistent with the loss of EGFP-expressing beta cells, MIP-EGFP mice that received Jedi T cells were diabetic, as indicated by their loss of glucose control (Fig. 1j) . npg l e t t e r s is mediated by microglia. Further work will be necessary to better understand the mechanisms involved. In particular, it will be relevant to determine if other antigen-presenting cells play a role through cross-presentation of antigen derived from the microglia. It will also be important to confirm our findings in a model in which irradiation was not used because we cannot rule out the possibility that irradiation had somehow altered the BBB. The rapid clearance of EGFP-expressing microglia and beta cells by the Jedi T cells led us to reason that these cells may also have utility as a method for depleting cells to study their function.
We first tested whether we could copy the phenotype of an established cell depletion model using Jedi T cells. We selected Foxp3 + regulatory T cells (T reg cells) as a target because the phenotype of T reg cell depletion is known 22 , although whether CD8 + T cells could kill T reg cells was unknown. In addition, T reg cells are a renewing population so we could use this model to assess the stability of cell depletion. To determine if Jedi T cells could be used to deplete T reg cells, we injected Foxp3-EGFP mice with Jedi or control T cells. In Foxp3-EGFP mice, EGFP has been knocked in to the Foxp3 gene on the X chromosome 23 . We initially injected heterozygous female Foxp3-EGFP mice. Due to random X-inactivation ~50% of the T reg cells were Foxp3 + EGFP + , and the other 50% were Foxp3 + EGFP − (Fig. 3a) . Within 6 days of injecting activated Jedi T cells, there was a complete elimination of Foxp3 + EGFP + cells (Fig. 3a,b) . The Foxp3 + EGFP − cells were not depleted but instead increased in numbers to compensate for the loss of the EGFP + T reg cells. Depletion was maintained for up to 14 days (the last time assessed) without any need to transfer more T cells or to revaccinate (Fig. 3b) , and the frequency of Jedi T cells contracted to very low levels (Fig. 3c) . Although tools are available to study antigen-dependent T-cell interactions with beta cells, those tools do not currently exist for many other cell types, such as, for microglia, brain-resident macrophages. It is unclear whether under brain homeostatic conditions CD8 + T cells survey microglia, as the blood brain barrier (BBB) is believed to keep the brain mostly inaccessible to cellular infiltrates in the absence of inflammation 16 . To study the antigen-presenting capacity of microglia, we took advantage of the CX3CR1-EGFP mice 17 , which express EGFP in microglia. Because CX3CR1 mice express EGFP also in circulating monocytes and some other myeloid cells, we used bone marrow transplant to create chimeric mice with EGFP + microglia, and red fluorescent protein (RFP) peripheral hematopoietic cells. To do this, we lethally irradiated the CX3CR1-EGFP mice, which ablated all the peripheral myeloid cells but spared microglia since they are radioresistant 18 , and transplanted bone marrow from actin-RFP mice into the irradiated recipients. After 10 weeks, the hematopoietic cells in the periphery were all RFP + and EGFP − , indicating that engraftment of the actin-RFP cells was complete, but the microglia were still EGFP + (Supplementary Fig. 3a-c) .
We transferred Jedi or control CD8 + T cells into the CX3CR1-EGFP/actin-RFP mice 10 weeks after the bone marrow transplant, a time by which the BBB has been fully repaired from irradiation and is not even permissible to serum albumin 19 . After transfer the mice were either vaccinated with EGFP or left unvaccinated to keep the T cells naive. Remarkably, within 1 week all of the EGFP + microglia were eliminated from mice that received Jedi T cells, even those that were not vaccinated (Fig. 2a,b and Supplementary Fig. 3d ). This was concomitant with the presence of Jedi T cells, but not control T cells, in the brain (Supplementary Fig. 3e,f) . The EGFP + microglia remained absent after 3 weeks, but there were RFP + macrophages (CD45 int Ly6c int CD11b + ) in the brain (Fig. 2b,c) , which is consistent with previous reports that peripheral monocytes can replace microglia after injury 20, 21 and extends this observation to the context of CD8 + T-cell-mediated clearance.
These findings indicate that naive T cells can enter the brain when microglia present an antigen recognized by the T cells and suggest the existence of an immune surveillance pathway for the brain that npg l e t t e r s Next, we injected male Foxp3-EGFP mice in which all Foxp3 + cells are EGFP + . Within 6 days there was complete depletion of Foxp3 + EGFP + T reg cells ( Fig. 3d and Supplementary Fig. 4a,b) . By 10 days all the Jedi-treated Foxp3-EGFP mice had become ill and showed clear indications of immune dysregulation, including conjunctivitis, splenomegaly, enlarged lymph nodes and expansion of neutrophils ( Fig. 3e and Supplementary Fig. 4c) , consistent with the phenotype of T reg -depleted mice 22 . We investigated the influence of T-cell dosage on target cell depletion by injecting Foxp3-EGFP male mice with 5 × 10 4 , 1.5 × 10 5 , or 5 × 10 5 CD8 + Jedi T cells. At the two highest cell doses, EGFP + cells were completely eliminated in all Foxp3-EGFP mice injected. At the lowest cell dose, EGFP + cells were eliminated in two out of three mice; in one mouse the Jedi T cells did not expand, and EGFP + cells were not eliminated ( Supplementary   Fig. 4d,e) . Thus, there appears to be a cell dose threshold for efficient killing, which is likely to depend on the nature of the EGFPexpressing mouse model.
To determine if we could use the Jedi to eliminate a rare cell population in a nonlymphoid organ, we targeted Hcn4 + cells. These cells are found in the heart and are extremely rare; there are <10,000 Hcn4 + cells in a mouse 24 . They are known to be involved in pacemaking, but there are conflicting reports regarding the overall importance of Hcn4 + cells in cardiac function 25, 26 . We injected Hcn4-EGFP mice 24 , which express EGFP under the control of the Hcn4 promoter, with Jedi or control T cells, and vaccinated them with EGFP. Within 5 days we could detect CD8 + T cells localizing with EGFP + cells in the heart (Fig. 4a) . Pentamer staining indicated that these cells were Jedi T cells (Fig. 4b) . Strikingly, by 10 days the Hcn4-EGFP cells were entirely npg l e t t e r s absent from the heart of the Hcn4-EGFP mice injected with Jedi T cells (Fig. 4c) . Unlike in other depletion technologies, we were able to assess target cell depletion at single-cell resolution using flow cytometry and confirm that the Jedi T cells completely eliminated the Hcn4 + cells from the hearts (Fig. 4d) . We then performed an electrocardiogram (ECG) on the mice after depletion of Hcn4 + cells to determine the outcome of depletion on cardiac function. Whereas mice injected with control T cells had a normal ECG, all mice injected with Jedi T cells had bradycardia and atrioventricular block (Fig. 4e and Supplementary Fig. 5 ). This was not due to immune cell infiltration or inflammation because after 10 days there was no evidence of increased T cells or pro-inflammatory cytokines in the hearts of the mice (Fig. 4f) . These findings support the role of Hcn4 + cells in cardiac conduction and pacemaking. They also demonstrate that Jedi T cells can home to and kill EGFPexpressing cells even in nonlymphoid, noninflamed tissue, and provide a means of targeted cell depletion.
There are many areas of immunological research where the Jedi will be particularly valuable because with them one can visualize the antigen and take advantage of the numerous existing EGFPexpressing reagents. These include identifying tolerogenic or immuneprivileged cell types, testing cell-targeted vaccines, monitoring T-cell trafficking to antigen-expressing cells in normal and diseased tissues, studying T-cell interactions with particular cell types and cell states within a primary and metastatic tumor, and for identifying cytotoxic T-lymphocyte-resistant cancer cells, which will be greatly facilitated by the ability to sort surviving cells by flow cytometry. It will also be possible to use the Jedi to create novel models of tissue autoimmunity and organ rejection, and for studying pathogen clearance, in a manner more accessible to state-of-the-art imaging, including live cell imaging. In addition to their relevance for basic biology, these applications of the Jedi will also facilitate target discovery and preclinical testing of immune modulatory drugs.
This work additionally demonstrates that Jedi T cells can be used for targeted cell depletion. The main advantages of this approach over existing cell depletion methods, such as the DTR system, are the ability to easily assess the elimination of the target cells using EGFP, the stability of depletion and the greater availability of cell type-specific EGFP-expressing models. Indeed, there are more than 1,000 different EGFP-expressing mice (e.g., Supplementary Table 1), many of which express EGFP in populations whose functions are not well characterized 10, 27 . We also note that Jedi T cell-mediated killing is a physiological method of cell depletion, as this is the natural function of CD8 + T cells. For this reason, there are mechanisms to control excessive tissue damage by T cells 28 . This is evident by the absence of inflammation and the contraction of the CD8 + T cells after antigen-expressing cells are cleared. For studies in which cell ablation is used to study tissue repair, T-cell-mediated depletion may better approximate physiological conditions as one of the causes of tissue regeneration is T-cell-mediated clearance of cells.
For the studies performed here we adoptively transferred CD8 + Jedi T cells, usually ~10 6 , and vaccinated the recipient mice to activate and expand the Jedi T cells. This was done to maximize the killing potential. However, the Jedi mouse could be bred directly with cell type-specific EGFP-expressing mice, or mice in which EGFP expression is inducible, as an alternative approach. For applications in which transient depletion is desired, the Jedi mice could be engineered to express a suicide gene, such as DTR, so that the Jedi T cells can be conditionally depleted. Because Jedi T cells recognize EGFP presented on H-2K d , they can be used in NOD/SCID-based mouse models, including human xenograft models. These applications of the Jedi mouse will enable dissection of the mechanisms by which T cells interact with discreet cell populations in different contexts at a very granular level, and help determine the function of cell types that have remained poorly characterized.
METhoDs
Methods and any associated references are available in the online version of the paper. collagenase IV (Sigma-Aldrich) for 15 min at 37 °C. After filtration using 70-µm cell strainer (Fisherbrand) to obtain a single-cell suspension, red blood cells (RBC) in the spleen were lysed with RBC lysis buffer (eBioscience) for 3 min. Brains were similarly digested; a Percoll gradient was used for the isolation of hematopoietic cells previous to the RBC lysis. Briefly, for the brain, single-cell suspensions were resuspended in a 37% Percoll (GE Healthcare) and underlayed by a 60% Percoll solution. The samples were then centrifuged at 600g for 20 min. Hearts were digested in 1 mg/ml collagenase IV in 10% FBS HBSS for 30 min at 37 °C and similarly filtered through a 70-µM cell strainer and RBC were lysed for 3 min.
The mRNA expression analysis. For measuring cytokine expression in tissue, hearts were collected from mice and immediately frozen in dry ice for later processing. For RNA extraction, tissue was homogenized in Trizol (Qiagen) by mechanical disruption by using the Tissue Disruptor (Qiagen) and the RNA was then extracted following the manufacturer's instructions. 0.1-1 µg total RNA was reverse-transcribed for 1 h at 37 °C using RNA-to-cDNA kit (Applied Biosystems). qPCR was performed using the SYBR green qPCR master mix 2× (Fermentas, Thermo Scientific) and the following primers:
Actin Fw: ctaaggccaaccgtgaaaag, actin Rev: accagaggcatacagggaca; IL6 Fw: TGATGGATGCTACCAAACTGG; IL6 Rev: TTCATGTACTCC AGGTAGCTATGG; MIP1α Fw: CAAGTCTTCTCAGCGCCATA; MIP1α Rev: GGAATCT TCCGGCTGTAGG; TNF Fw: CTGTAGCCCACGTCGTAGC; TNF Rev: TTTGAGATCCA TGCCGTTG.
TCR sequencing. To obtain the specific alpha and beta sequences of the Jedi T cells, splenocytes from a Jedi mouse were stained with a CD3e-PE, CD8a-FITC antibodies and GFP 200-208 -H2K d APC pentamer as described above. Pentamer + CD8 T cells were FACS-sorted in Influx Cell Sorter (BD Biosciences) and resuspended in Trizol. RNA was isolated as described above. 5′RACE (Invitrogen) was performed following the manufacturer's instructions to amplify the alpha and beta regions. A 3′ primer recognizing the constant region in alpha and the constant region in beta were used, respectively. The DNA fragment obtained was cloned into a TOPO plasmid (Invitrogen) following the manufacturer's instructions and submitted to sequencing by Sanger method. Cα primer: TGGCGTTGGTCTCTTTGAAG; Cβ primer; CCAGAAGGTAGCAGAGACCC.
Statistical analysis.
No prespecified effect size was used to determine sample sizes. Differences between groups were compared by independent two tailed Student's t-test for unequal variances. P < 0.05 was considered statistically significant.
